Analysts’ Recent Ratings Updates for Illumina (ILMN)

A number of research firms have changed their ratings and price targets for Illumina (NASDAQ: ILMN):

• 11/2/2026 – Illumina was upgraded by Weiss Ratings from “hold (c)” to “buy (b-)”.
• 11/2/2026 – Illumina had its price target raised by Citigroup from $113.00 to $210.00. They now have a “sell” rating on the stock.
• 10/30/2026 – Illumina had its “underperform” rating reaffirmed by Evercore.
• 10/30/2026 – Illumina had its price target lowered by JPMorgan Chase & Co. from $320.00 to $300.00. They now have an “overweight” rating on the stock.
• 10/23/2026 – Illumina was downgraded by Stephens from “overweight” to “equal weight”. They now have a $275.00 price target on the stock.
• 10/23/2026 – Illumina was downgraded by Stephens from “overweight” to “equal weight”. They now have a $275.00 price target on the stock.
• 10/19/2026 – Illumina had its price target raised by Canaccord Genuity Group from $205.00 to $300.00. They now have a “hold” rating on the stock.
• 10/13/2026 – Illumina had its price target raised by TD Cowen from $210.00 to $270.00. They now have a “hold” rating on the stock.
• 10/11/2026 – Illumina was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/7/2026 – Illumina had its price target raised by Barclays from $160.00 to $200.00. They now have an “underweight” rating on the stock.
• 10/5/2026 – Illumina had its price target raised by Royal Bank Of Canada from $230.00 to $310.00. They now have an “outperform” rating on the stock.
• 10/3/2026 – Illumina was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/1/2026 – Illumina had its price target raised by Guggenheim from $226.00 to $305.00. They now have a “buy” rating on the stock.
• 9/29/2026 – Illumina had its price target raised by Leerink Partners from $220.00 to $300.00. They now have an “outperform” rating on the stock.
• 9/28/2026 – Illumina had its price target raised by Piper Sandler from $225.00 to $305.00. They now have an “overweight” rating on the stock.
• 9/9/2026 – Illumina was upgraded by UBS Group from “neutral” to “buy”. They now have a $260.00 price target on the stock, up from $135.00.

Illumina Stock Down 4.8%

Shares of Illumina stock traded down $11.52 on Wednesday, hitting $226.69. The company had a trading volume of 930,720 shares, compared to its average volume of 2,175,188. The stock has a 50-day moving average of $249.74 and a 200-day moving average of $177.05. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.63 and a quick ratio of 2.05. Illumina, Inc. has a twelve month low of $112.65 and a twelve month high of $309.35. The firm has a market capitalization of $34.28 billion, a P/E ratio of 39.02, a P/E/G ratio of 3.08 and a beta of 1.46.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.26. The company had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.15 billion. Illumina had a return on equity of 28.38% and a net margin of 19.72%. Illumina’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.34 earnings per share. Research analysts predict that Illumina, Inc. will post 5.43 earnings per share for the current year.

Insider Transactions at Illumina

In other Illumina news, SVP Christensen Wedel sold 1,033 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president directly owned 14,023 shares in the company, valued at $2,685,684.96. This trade represents a 6.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 299,336 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $217.96, for a total value of $65,243,274.56. Following the transaction, the director directly owned 1,409,851 shares in the company, valued at $307,291,123.96. This trade represents a 17.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 1,320,108 shares of company stock valued at $288,195,392. Company insiders own 2.90% of the company’s stock.

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.